TScan Therapeutics, Inc. (TCRX)
Develops engineered T cell therapies to fight cancer and blood disorders
$0.77+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-52.2%
The outlook
TCRX trades at $0.77, well below both its 50- and 200-day moving averages and sitting near its 52-week low. Analyst coverage leans bullish on price targets, with the average target implying substantial upside from current levels, though the overall StockGlow score reflects a bearish lean. The stock's positioning suggests elevated risk alongside analyst optimism.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +675% vs current price
Analyst price target
~12-month · 4 analysts$6.00average target+675.2% vs now
Now $0.77
Low $5.00High $7.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$50.6M
52-wk high
$2.57
52-wk low
$0.73
50-day avg
$0.97
200-day avg
$1.15
Trailing P/E
—